Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

a study in type 1 diabetes patients who receive their insulin treatment via pump. The study demonstrated that pre-administration of rHuPH20 led to consistent insulin exposure over the infusion set life and better glucose control following meals.
  • Reported results from two Phase 2 clinical trials of its ultrafast rHuPH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to insulin analog. rHuPH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently (i.e. during at least 2/3 of meals) achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets at both one and two hours after meals in both Type 1 and Type 2 patients.
  • Initiated a Phase 2 study with PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
  • Initiated a Phase 1/2 study with HTI-501 in women with moderate to severe edematous fibrosclerotic panniculopathy, or cellulite.
  • Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology.  HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of IgG using a single site with very good local and systemic tolerability.  Systemic infusion reactions occurred in 8.3% of HyQ infusions compared to 25% of infusions in the IV arm. HyQ also demonstrated improved bioavailability compared to IGSC and similar trough levels to IGIV when administered at 3 or 4-week intervals, at infusion rates and times faster than IGIV.  Baxter submitted regulatory applications in the US in the second quarter and in the EU in the third quarter.
  • Achieved a $3 million milestone under ViroPharma agreement triggered by ViroPharma's initiation of an open-label, multi-dose Phase 2 study of Cinryze
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
    (Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
    (Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
    (Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
    Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
    ... Blue Steel-Al Manhal Consortium, he stated that the agreement made would ... countries, cities, and governmental entities to solve the environmental ... ... (PRWEB) July 30, 2008 -- Spectrum Blue Steel Corporation announced today ...
    ... designed to accelerate recovery from central nervous system disorders, announced ... rehabilitative healthcare services, will expand the availability of the NESS ... System to 88 rehabilitation hospitals nationwide. , ... ...
    ... Development Of Lead Drug Candidates, MARKHAM, ON, ... of a CDN $45 million Series C financing. ... Tanabe Pharma Corporation ("MTPC"), and supported,by a number ... Inc., Caisse de Depot et Placement du Quebec, ...
    Cached Biology Technology:Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
    (Date:4/23/2014)... away from using triclosan as an antimicrobial ingredient in ... now scientists are reporting new evidence that appears to ... journal Chemical Research in Toxicology , found that ... promoted the growth of human breast cancer cells in ... Kyung-Chul Choi and colleagues note that hormonal imbalances seem ...
    (Date:4/23/2014)... EMBO today announced Sophie Martin of the University ... EMBO Gold Medal. The award acknowledges her work to ... development of the cell. , Martin has been working ... in particular the way in which the spatial organization ... In the last 11 years, she has been using ...
    (Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
    Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
    ... Jerusalem, January 11, 2010 Why do some people ... the other hand, taking the opposite tack by buying insurance ... from the Hebrew University of Jerusalem and two Asian universities ... The team set out to tackle the long-standing question ...
    ... an enzyme in the brain with a specific kind of ... stroke, new research suggests. In a study using mouse ... E, an alternative to the popular drugstore supplement, stopped the ... The Ohio State University researchers have been studying how this ...
    ... unknown species of spider has been discovered in the dune ... by a team of scientists from the Department of Biology ... endangered. "The discovery of this new spider illustrates our obligation ... team of scientists. The Sands of Samar are the ...
    Cached Biology News:Why do people 'play the longshot' and buy insurance? It's in our genes 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3New spider species discovered by University of Haifa scientists 2
    96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
    ...
    The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
    ... Fixed Angle Polypropylene Rotor designed for ... Centra CL3/CL3R** and Centra-MP4/MP4R*. A translucent ... /MP4, ,EXCLUSIVE polypropylene rotor design provides ... repeatedly autoclaved. Polypropylene rotors are ...
    Biology Products: